Oslo, Norway, 29 June – 2 July 2019
Patients with episodic or chronic migraine who took monthly or quarterly fremanezumab during the FOCUS trial required significantly less health-related time off work during the four weeks after the third dose of study drug, compared to placebo (Table 1).1 They also experienced fewer days when their work or activities were impaired by their health. “The …
Read more »Long term treatment with erenumab is associated with a sustained reduction in physical impairment and an improved ability to participate in daily activities, according to the latest analysis of data from the open label extension (OLE) of the LIBERTY trial in patients with episodic migraine who failed on two to four previous preventive therapies. At …
Read more »Reductions in migraine headache days with galcanezumab reported in the EVOLVE and REGAIN trials are associated with lower levels of migraine-related disability and greater improvements in daily functioning than placebo, according to a further analysis of study data.1,2 According to pooled data from EVOLVE 1 and 2 in episodic migraine, 44% of patients treated with …
Read more »Smartphone Apps may have become an essential part of everyday life, but they have yet to take over from paper diaries for recording migraine headaches – at least in Spain. Results of a prospective survey of 411 patients with migraine treated at a headache unit in Madrid, Spain, have shown that only five patients (1.21%) …
Read more »Migraine researchers must not be discouraged from searching for molecular biomarkers for migraine by previous disappointments. The complexity of the disease should stimulate further research with improved methodology based on rigorous and informative tools for data collection, careful clinical and diagnostic subgrouping of patients, literature analysis, cutting-edge biodata analysis and possibly the selection of a …
Read more »Clinicians should screen for metabolic syndrome in patients with more severe migraine. This is the advice of researchers who have shown statistically significant relationships between metabolic parameters and migraine. In a descriptive-analytical cross-sectional study, 240 migraineurs in the 17+ age range were investigated for migraine characteristics (intensity, frequency of attacks, subtype, duration, and treatment regimen) …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
